PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	aldo-keto reductase family 1 member B1	Ictalurus punctatus	67-73
21329680-5	2011	AKR1B1 (aldose reductase) is related to secondary diabetic complications, while AKR1B10 is induced in cancer cells and is highly active with all-trans-retinaldehyde.	Retinaldehyde	141-164	aldo-keto reductase family 1 member B1	Ictalurus punctatus	0-6
21215737-0	2011	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.	Bortezomib	33-43	aldo-keto reductase family 1 member B1	Ictalurus punctatus	67-73
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	Bortezomib	45-55	aldo-keto reductase family 1 member B1	Ictalurus punctatus	100-106
21215737-5	2011	The present study investigated the effect of bortezomib and MG-132 on the expression of AKR1C1-1C4, AKR1B1, and AKR1B10 in colon cancer cell lines HT-29 and SW-480.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	60-66	aldo-keto reductase family 1 member B1	Ictalurus punctatus	100-106